Bruno Marchou

Bruno Marchou

Auto-generated profile, based on publicly available information

Bruno Marchou

Department of Infectious and Tropical Diseases, Toulouse University Hospital, Place du Docteur Baylac TSA 40031, 31059, Toulouse CEDEX 9, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JMJEAN MICHEL MANSUY
JEAN MICHEL MANSUY
MDMarine Dutertre
Marine Dutertre
CMCatherine Mengelle
Catherine Mengelle
CFCamille Fourcade
Camille Fourcade
BMBruno Marchou
Bruno Marchou
GMGuillaume Martin-Blondel
Guillaume Martin-Blondel

1 October 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JMJEAN MICHEL MANSUY
JEAN MICHEL MANSUY
ESElsa Suberbielle
Elsa Suberbielle
SCSabine Chapuy-Regaud
Sabine Chapuy-Regaud
CMCatherine Mengelle
Catherine Mengelle
LBLouis Bujan
Louis Bujan
GMGuillaume Martin-Blondel
Guillaume Martin-Blondel

21 April 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
ACAntoine Chéret
Antoine Chéret
CBCharline Bacchus-Souffan
Charline Bacchus-Souffan
VAVéronique Avettand-Fenoel
Véronique Avettand-Fenoel
AMAdeline Mélard
Adeline Mélard
GNGeorges Nembot
Georges Nembot
ACA. Cabié
A. Cabié
Therapeutic control of HIV replication reduces the size of the viral reservoir, particularly among central memory CD4+ T cells, and this effect might be accentuated by early treatment. We examined the effect of ART initiated at the time of the primary HIV infection (early ART), lasting 2 and 6 years in 11 and 10 patients, respectively, on the HIV reservoir in peripheral resting CD4+ T cells, sorted into naive (TN), central memory (TCM), transitional memory (TTM) and effector memory (TEM) cells, by comparison with 11 post-treatment controllers (PTCs). Between baseline and 2 years, CD4+ T cell subset numbers increased markedly (P < 0.004) and HIV DNA levels decreased in all subsets (P < 0.009). TTM cells represented the majority of reservoir cells at both timepoints, T cell activation status normalized and viral diversity remained stable over time. The HIV reservoir was smaller after 6 years of early ART than after 2 years (P < 0.019), and did not differ between PTCs and patients treated for 6 years. One patient, who had low reservoir levels in all T cell subsets after 2 years of treatment similar to the levels in PTCs, spontaneously controlled viral replication during 18 months off treatment. Early prolonged ART thus limits the size of the HIV reservoir, protects long-lived cells from persistent infection and may enhance post-treatment control.

29 July 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CBCaroline Besson
Caroline Besson
RLRemi Lancar
Remi Lancar
SPSophie Prevot
Sophie Prevot
PBPauline Brice
Pauline Brice
MMMarie-Caroline Meyohas
Marie-Caroline Meyohas
DCDominique Costagliola
Dominique Costagliola
Background. Human immunodeficiency virus (HIV) infection is associated with a high risk of classical Hodgkin's lymphoma (cHL) in the combined antiretroviral therapy (cART) era. Methods. We analyzed the characteristics and outcome of HIV-associated cHL diagnosed in the modern cART era. The French ANRS-CO16 Lymphovir cohort enrolled 159 HIV-positive patients with lymphoma, including 68 (43%) with cHL. HIV-HL patients were compared with a series of non-HV-infected patients consecutively diagnosed with HL. Results. Most patients (76%) had Ann-Arbor stages III-IV and 96% of patients were treated with ABVD. At diagnosis, median CD4 T-cell count was 387/µL and 94% of patients were treated with cART. All patients received cART after diagnosis. Five patients died from early progression (n = 2), sepsis (1) or after relapse (2). Two additional patients relapsed during follow-up. Two-year overall and progression free survivals (PFS) were 94% [95% CI, 89%, 100%] and 89% [82%, 97%], respectively. The only factor associated with progression or death was age with a relative risk of 8.1 [1.0; 67.0] above 45 years. The PFS of Lymphovir patients appeared similar to PFS of HIV-negative patients, 86% [82%, 90%], but patients with HIV infection displayed higher risk features than HIV-negative patients. Conclusions. Although high-risk features still predominate in HIV-HL, the prognosis of these patients, treated with cART and mainly ABVD, has markedly improved in the modern cART era and is now similar to non-HIV-infected patients.

7 January 2016 in Eurosurveillance
Verified
Journal Article
Open access
ABAntoine Berry
Antoine Berry
JFJudith Fillaux
Judith Fillaux
GMGuillaume Martin-Blondel
Guillaume Martin-Blondel
JBJérôme Boissier
Jérôme Boissier
XIXavier Iriart
Xavier Iriart
PDPierre Delobel
Pierre Delobel
We present a case of acute schistosomiasis acquired in Corsica after bathing in the Cavu River during the summer of 2015. The diagnosis was made following epidemiological, laboratory and serological assessments. After a previous outbreak of urogenital schistosomiasis during the summer of 2013, when more than 120 infections were diagnosed, this further case indicates transmission was still effective in 2015, thus suggesting a permanent presence of schistosomiasis in Corsica.

3 January 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SFSlim Fourati
Slim Fourati
CCCharlotte Charpentier
Charlotte Charpentier
CACorinne Amiel
Corinne Amiel
LMLaurence Morand-Joubert
Laurence Morand-Joubert
SRSandrine Reigadas
Sandrine Reigadas
ETE. Teicher
E. Teicher
The objectives of this study were to determine the prevalence and patterns of resistance to integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART and the impact on susceptibility to INSTIs (raltegravir, elvitegravir and dolutegravir). Data were collected from 502 treatment-experienced patients failing a raltegravir-containing regimen in a multicentre study. Reverse transcriptase, protease and integrase were sequenced at failure for each patient. INSTI resistance-associated mutations investigated were those included in the last ANRS genotypic algorithm (v23). Among the 502 patients, at failure, median baseline HIV-1 RNA (viral load) was 2.9 log10 copies/mL. Patients had been previously exposed to a median of five NRTIs, one NNRTI and three PIs. Seventy-one percent harboured HIV-1 subtype B and the most frequent non-B subtype was CRF02_AG (13.3%). The most frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and Y143C/G/H/R/S (6.7%). At failure, viruses were considered as fully susceptible to all INSTIs in 61.0% of cases, whilst 38.6% were considered as resistant to raltegravir, 34.9% to elvitegravir and 13.9% to dolutegravir. In the case of resistance to raltegravir, viruses were considered as susceptible to elvitegravir in 11% and to dolutegravir in 64% of cases. High HIV-1 viral load at failure (P < 0.001) and low genotypic sensitivity score of the associated treatment with raltegravir (P < 0.001) were associated with the presence of raltegravir-associated mutations at failure. Q148 mutations were selected more frequently in B subtypes versus non-B subtypes (P = 0.004). This study shows that a high proportion of viruses remain susceptible to dolutegravir in the case of failure on a raltegravir-containing regimen.